Osborne Partners Capital Management LLC Has $164,000 Holdings in IRIDEX Co. (IRIX)

Osborne Partners Capital Management LLC decreased its position in shares of IRIDEX Co. (NASDAQ:IRIX) by 14.3% during the 1st quarter, HoldingsChannel reports. The fund owned 36,000 shares of the medical equipment provider’s stock after selling 6,000 shares during the period. Osborne Partners Capital Management LLC’s holdings in IRIDEX were worth $164,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its position in shares of IRIDEX by 3.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 207,148 shares of the medical equipment provider’s stock worth $974,000 after acquiring an additional 7,404 shares in the last quarter. Neuberger Berman Group LLC boosted its position in shares of IRIDEX by 60.0% during the 3rd quarter. Neuberger Berman Group LLC now owns 24,000 shares of the medical equipment provider’s stock worth $152,000 after acquiring an additional 9,000 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of IRIDEX by 2.8% during the 3rd quarter. Vanguard Group Inc. now owns 403,547 shares of the medical equipment provider’s stock worth $2,563,000 after acquiring an additional 11,000 shares in the last quarter. Vanguard Group Inc boosted its position in shares of IRIDEX by 2.8% during the 3rd quarter. Vanguard Group Inc now owns 403,547 shares of the medical equipment provider’s stock worth $2,563,000 after acquiring an additional 11,000 shares in the last quarter. Finally, Quantum Capital Management boosted its position in shares of IRIDEX by 83.2% during the 4th quarter. Quantum Capital Management now owns 28,829 shares of the medical equipment provider’s stock worth $135,000 after acquiring an additional 13,089 shares in the last quarter. Institutional investors and hedge funds own 45.26% of the company’s stock.

IRIX has been the topic of several analyst reports. Zacks Investment Research upgraded shares of IRIDEX from a “sell” rating to a “hold” rating in a research report on Friday, December 28th. ValuEngine lowered shares of IRIDEX from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Stifel Nicolaus reduced their price target on shares of IRIDEX from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, January 4th. Finally, Roth Capital reissued a “buy” rating on shares of IRIDEX in a research note on Tuesday, February 5th.

NASDAQ:IRIX traded down $0.20 on Wednesday, hitting $4.65. The company had a trading volume of 14,647 shares, compared to its average volume of 21,701. The company has a market cap of $70.35 million, a price-to-earnings ratio of -4.43 and a beta of 1.03. IRIDEX Co. has a 52 week low of $3.72 and a 52 week high of $9.48.

IRIDEX (NASDAQ:IRIX) last issued its quarterly earnings data on Tuesday, March 5th. The medical equipment provider reported ($0.21) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.04. The business had revenue of $11.47 million during the quarter, compared to the consensus estimate of $10.85 million. IRIDEX had a negative net margin of 30.08% and a negative return on equity of 44.86%. As a group, equities analysts predict that IRIDEX Co. will post -0.83 earnings per share for the current fiscal year.

WARNING: “Osborne Partners Capital Management LLC Has $164,000 Holdings in IRIDEX Co. (IRIX)” was first posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/24/osborne-partners-capital-management-llc-has-164000-holdings-in-iridex-co-irix.html.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.

Recommended Story: 52-Week High/Low Prices For Stock Selection

Want to see what other hedge funds are holding IRIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IRIDEX Co. (NASDAQ:IRIX).

Institutional Ownership by Quarter for IRIDEX (NASDAQ:IRIX)

Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.